272 related articles for article (PubMed ID: 35941070)
1. SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.
Summers RJ; Teachey DT
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):718-725. PubMed ID: 35941070
[TBL] [Abstract][Full Text] [Related]
2. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
Si Lim SJ; Ford JB; Hermiston ML
Blood; 2023 Jun; 141(25):3019-3030. PubMed ID: 37018730
[TBL] [Abstract][Full Text] [Related]
3. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.
Patel J; Gao X; Wang H
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108359
[TBL] [Abstract][Full Text] [Related]
4. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.
Maciocia PM; Wawrzyniecka PA; Maciocia NC; Burley A; Karpanasamy T; Devereaux S; Hoekx M; O'Connor D; Leon T; Rapoz-D'Silva T; Pocock R; Rahman S; Gritti G; Yánez DC; Ross S; Crompton T; Williams O; Lee L; Pule MA; Mansour MR
Blood; 2022 Jul; 140(1):25-37. PubMed ID: 35507686
[TBL] [Abstract][Full Text] [Related]
5. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
Bayón-Calderón F; Toribio ML; González-García S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081391
[TBL] [Abstract][Full Text] [Related]
6. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
Jeha S
Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
[TBL] [Abstract][Full Text] [Related]
7. Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia.
Aldoss I; Tizro P; Bedi D; Mangan JK; Clark MC; Spencer D; Song JY; Cherian S; Pillai R; Kim Y; Mahajan N; Gendzekhadze K; James M; Jacobs K; Davidson-Moncada J; Forman SJ; Wang HY; Afkhami M
Haematologica; 2023 Dec; 108(12):3511-3516. PubMed ID: 37470155
[No Abstract] [Full Text] [Related]
8. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract][Full Text] [Related]
9. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
[No Abstract] [Full Text] [Related]
10. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
Teachey DT; Devidas M; Wood BL; Chen Z; Hayashi RJ; Hermiston ML; Annett RD; Archer JH; Asselin BL; August KJ; Cho SY; Dunsmore KP; Fisher BT; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju AI; Lam A; Messinger YH; Miles RR; Okada M; Patel SI; Schafer ES; Schechter T; Singh N; Steele AC; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay P; Bollard CM; Loh ML; Hunger SP; Raetz EA
J Clin Oncol; 2022 Jul; 40(19):2106-2118. PubMed ID: 35271306
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
Huang YH; Wan CL; Dai HP; Xue SL
Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults.
Temple WC; Mueller S; Hermiston ML; Burkhardt B
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101449. PubMed ID: 36907639
[TBL] [Abstract][Full Text] [Related]
13. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
14. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
Aldoss I; Forman SJ
Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
[TBL] [Abstract][Full Text] [Related]
15. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe.
Din RU; Jiao A; Qiu Y; Mohan AAM; Yuen KC; Wong HT; Wan TM; Wong PO; Sin CF
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834095
[TBL] [Abstract][Full Text] [Related]
17. T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development.
Thomas X
Expert Opin Investig Drugs; 2023 Jan; 32(1):37-52. PubMed ID: 36541671
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
19. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
20. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]